Man Group plc Buys Shares of 15,847 iRadimed Corporation $IRMD

Man Group plc bought a new position in shares of iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, HoldingsChannel reports. The fund bought 15,847 shares of the medical equipment provider’s stock, valued at approximately $1,514,000.

A number of other institutional investors have also made changes to their positions in IRMD. Farther Finance Advisors LLC raised its stake in shares of iRadimed by 827.1% in the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the period. Quarry LP acquired a new position in shares of iRadimed in the 3rd quarter worth approximately $40,000. CWM LLC boosted its position in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. Finally, Global Retirement Partners LLC acquired a new stake in iRadimed in the 4th quarter valued at approximately $85,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Trading Down 0.2%

NASDAQ:IRMD opened at $86.17 on Thursday. The firm has a market cap of $1.10 billion, a PE ratio of 48.14 and a beta of 0.89. The stock has a fifty day moving average price of $92.56 and a 200 day moving average price of $93.82. iRadimed Corporation has a 12-month low of $67.84 and a 12-month high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities analysts forecast that iRadimed Corporation will post 1.98 EPS for the current year.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Investors of record on Friday, August 14th were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is 44.69%.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Wall Street Zen lowered iRadimed from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings lowered iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.